申请人:Hayashibe Satoshi
公开号:US20090186916A1
公开(公告)日:2009-07-23
Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain.
A novel compound or a salt thereof, which is characterized in that it has an amino group and R
1
(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R
2
and R
3
(the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.
提供的化合物是一种N
MDA受体拮抗剂,具有更广泛的安全边际,可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕
金森病、缺血性卒中或疼痛的药剂。
一种新型化合物或其盐,其特征在于在
茚烷、环戊[b]
噻吩、环戊[b]
呋喃、环戊[b]
吡啶或环戊[c]
吡啶环的碳原子上具有
氨基和R1(较低的烷基、环烷基、-较低的烷基-芳基、可能被取代的芳基等),或2,3-二氢-1-
苯并呋喃、2,3-二氢-1-
苯并噻吩、
吲哚环或类似物,并且在它们旁边的碳原子上具有R2和R3(相同或不同,每个都是较低的烷基或芳基),以及包含其作为活性成分的N
MDA受体拮抗剂。